应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
03692 翰森制药
未开盘 09-01 16:08:13
34.360
-0.980
-2.77%
最高
35.680
最低
34.140
成交量
1,082万
今开
35.680
昨收
35.340
日振幅
4.36%
总市值
2,084亿
流通市值
2,084亿
总股本
60.64亿
成交额
3.74亿
换手率
0.18%
流通股本
60.64亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
里昂：翰森制药重申“跑赢大市”评级 目标价上调至43.70港元
新浪港股 · 09-01 13:03
里昂：翰森制药重申“跑赢大市”评级 目标价上调至43.70港元
异动解读｜翰森制药盘中下跌3.28%，绩后获利回吐延续叠加制药板块偏弱
行情直击 · 09-01 10:47
异动解读｜翰森制药盘中下跌3.28%，绩后获利回吐延续叠加制药板块偏弱
里昂：重申翰森制药(03692.HK)“跑赢大市”评级 目标价上调至43.7港元
智通财经 · 08-31 17:47
里昂：重申翰森制药(03692.HK)“跑赢大市”评级 目标价上调至43.7港元
小摩：维持翰森制药(03692)“增持”评级 目标价上调至50港元
智通财经 · 08-31 17:13
小摩：维持翰森制药(03692)“增持”评级 目标价上调至50港元
异动解读｜翰森制药盘中下跌3.16%，绩后冲高回落叠加制药板块集体走弱
行情直击 · 08-31 09:48
异动解读｜翰森制药盘中下跌3.16%，绩后冲高回落叠加制药板块集体走弱
高盛：予翰森制药(03692)“买入”评级 目标价上调至52.7港元
智通财经 · 08-27
高盛：予翰森制药(03692)“买入”评级 目标价上调至52.7港元
绩后涨超16%，翰森的增长从哪里来？
华尔街见闻 · 08-27
绩后涨超16%，翰森的增长从哪里来？
大摩：上调翰森制药(03692.HK)目标价至48港元 维持“增持”评级
智通财经 · 08-27
大摩：上调翰森制药(03692.HK)目标价至48港元 维持“增持”评级
翰森制药（03692）上涨超10% 中期收入增长约11.7%
金吾财讯 · 08-27
翰森制药（03692）上涨超10% 中期收入增长约11.7%
港股异动 | 翰森制药涨超12%，上半年纯利同比增长35.82%，创新药收入占比超85%
智通财经 · 08-27
港股异动 | 翰森制药涨超12%，上半年纯利同比增长35.82%，创新药收入占比超85%
港股异动 | 翰森制药(03692.HK)涨超10% 上半年纯利同比增长35.82% 创新药收入占比超85%
智通财经 · 08-27
港股异动 | 翰森制药(03692.HK)涨超10% 上半年纯利同比增长35.82% 创新药收入占比超85%
异动解读｜翰森制药盘中上涨5.73%，中期净利润同比大增35.8%
行情直击 · 08-27
异动解读｜翰森制药盘中上涨5.73%，中期净利润同比大增35.8%
港股开盘向好 恒指高开0.48% 翰森制药（03692）涨5.29%
金吾财讯 · 08-27
港股开盘向好 恒指高开0.48% 翰森制药（03692）涨5.29%
翰森制药：创新药龙头企业上半年收入稳健增至83.04亿元，创新药收入占比达85.4%
格隆汇 · 08-26
翰森制药：创新药龙头企业上半年收入稳健增至83.04亿元，创新药收入占比达85.4%
翰森制药(03692)发布中期业绩 股东应占溢利42.58亿元 同比增加35.82%
智通财经 · 08-26
翰森制药(03692)发布中期业绩 股东应占溢利42.58亿元 同比增加35.82%
翰森制药2026年中期财报：营收83.04亿元，净利润42.58亿元
公告速递 · 08-26
翰森制药2026年中期财报：营收83.04亿元，净利润42.58亿元
翰森制药宣布派发中期股息，每股28.50港仙
美股速递 · 08-26
翰森制药宣布派发中期股息，每股28.50港仙
异动解读｜翰森制药盘中下跌3.26%，报31.92港元
行情直击 · 08-24
异动解读｜翰森制药盘中下跌3.26%，报31.92港元
异动解读｜翰森制药盘中下跌3.09%，报32.58港元
行情直击 · 08-21
异动解读｜翰森制药盘中下跌3.09%，报32.58港元
【生物医药小白投研】第一篇：打破认知盲区，建立底层框架
港股解码 · 08-20
【生物医药小白投研】第一篇：打破认知盲区，建立底层框架
暂无数据
公司概况
公司名称：
翰森制药
所属市场：
SEHK
上市日期：
--
主营业务：
翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。
发行价格：
--
{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":34.36,"timestamp":1788250093007,"preClose":35.34,"halted":0,"volume":10821264,"delay":0,"changeRate":-0.02773061686474261,"floatShares":6064000000,"shares":6064000000,"eps":1.0847156097101995,"marketStatus":"未开盘","change":-0.98,"latestTime":"09-01 16:08:13","open":35.68,"high":35.68,"low":34.14,"amount":373538958,"amplitude":0.043577,"askPrice":34.38,"askSize":24000,"bidPrice":34.36,"bidSize":84000,"shortable":3,"etf":0,"ttmEps":1.2919581082909921,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":35.34,"dividendRate":0.014373,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":0.613748933862706,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692/tweets","defaultTab":"tweets","newsList":[{"id":"2664838275","title":"里昂：翰森制药重申“跑赢大市”评级 目标价上调至43.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664838275","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664838275?lang=zh_cn&edition=full","pubTime":"2026-09-01 13:03","pubTimestamp":1788238980,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端里昂发布研报称，翰森制药（03692）上半年业绩胜预期，收入同比增长12%，尽管监管环境严峻，报告/基础净利（剔除一次性收益）分别同比上升36%/19%。管理层重申2026年收入双位数增长指引，涵盖产品销售及BD收入。该行对公司全球扩张及2027年后新产品周期保持乐观，将目标价由42港元上调至43.7港元，并重申“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-01/doc-iniqhwna1617903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193753522","title":"异动解读｜翰森制药盘中下跌3.28%，绩后获利回吐延续叠加制药板块偏弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1193753522","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193753522?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:47","pubTimestamp":1788230865,"startTime":"0","endTime":"0","summary":"9月1日，翰森制药盘中下跌3.28%，报34.16港元/股，成交额1.38亿港元。公司此前因中期业绩超预期于8月27日大涨逾16%，随后连续回落，绩后获利回吐压力延续。消息面上，公司上半年收入同比增长11.7%至83.04亿元，溢利同比增长35.8%至42.58亿元，创新药收入占比升至85.4%。此外，制药板块今日整体偏弱，绿叶制药跌2.58%、中国生物制药跌1.86%，行业情绪低迷进一步拖累股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药绩后回落，制药板块承压拖累","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663774079","title":"里昂：重申翰森制药(03692.HK)“跑赢大市”评级 目标价上调至43.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663774079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663774079?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:47","pubTimestamp":1788169638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03692","BK1583","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076172","title":"小摩：维持翰森制药(03692)“增持”评级 目标价上调至50港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663076172?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:13","pubTimestamp":1788167636,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，维持翰森制药(03692)“增持”评级，基于上半年业绩，摩通将翰森制药今年全年合作收入预测上调4%，因新产品获批，能见度提升而轻微上调长期收入预测，目标价由45港元上调至50港元。翰森制药上半年业绩胜预期，收入同比增长11.7%至83.04亿元人民币，主要由创新药及合作收入带动，对收入贡献提升至85.4%。期内纯利同比增长35.8%至42.58亿元人民币，创半年度新高，惟当中有部分是来自生命科学领域未上市创投的一次性收益。管理层在业绩会上透露明年将有五个新产品获批，2030年累计有30个新产品获批，摩通认为可增强市场对其管线进展的信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183338039","title":"异动解读｜翰森制药盘中下跌3.16%，绩后冲高回落叠加制药板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1183338039","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183338039?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:48","pubTimestamp":1788140899,"startTime":"0","endTime":"0","summary":"8月31日，翰森制药盘中下跌3.16%，报35.2港元/股，成交额9967.51万港元。公司此前因中期业绩超预期于8月27日大涨逾16%，随后连续回落。有市场观点指出，当前估值已充分反映乐观预期，新品上市带来的销售费用扩张及医保谈判降价压力或制约利润空间，绩后获利回吐情绪明显。此外，制药板块今日普遍承压，绿叶制药跌7.75%、石药集团跌3.1%、中国生物制药跌3.04%、恒瑞医药跌1.75%，行业整体走弱进一步拖累股价表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药绩后走弱，制药板块集体承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662244777","title":"高盛：予翰森制药(03692)“买入”评级 目标价上调至52.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662244777","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662244777?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:25","pubTimestamp":1787822717,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，翰森制药(03692)上半年业绩胜预期，受创新药销售、营运杠杆及投资收益带动，目标价由50.1港元上调至52.7港元，并上调2026年盈利预测15%，评级“买入”。管理层重申2026财年产品销售及BD收入双位数增长指引，受强劲产品管线及预期2027年开始的新产品周期所支持。该行相信第二波创新产品及ADC产品系列将成为关键增长动力，使组合从单一产品走向多元化，支持可持续长期增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662077248","title":"绩后涨超16%，翰森的增长从哪里来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2662077248","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662077248?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:58","pubTimestamp":1787821087,"startTime":"0","endTime":"0","summary":"创新药收入增长不依赖销售费用同步扩张，海外临床推进则提高合作项目兑现里程碑和销售分成的可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662779428","title":"大摩：上调翰森制药(03692.HK)目标价至48港元 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662779428?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:41","pubTimestamp":1787816517,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1589","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662572136","title":"翰森制药（03692）上涨超10% 中期收入增长约11.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662572136","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662572136?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:43","pubTimestamp":1787794995,"startTime":"0","endTime":"0","summary":"金吾财讯 | 翰森制药（03692）盘初快速上涨，最新上涨超10%，报34.8港元，成交额1.42亿港元。消息面上，8月26日，翰森制药发布2026年中期业绩公告。2026年上半年收入约83.04亿元（人民币，下同），同比增长约11.7%；溢利约42.58亿元，同比增长约35.8%。每股基本盈利约0.70元，同比增长约33.1%。期内，集团创新药收入约70.92亿元，占总收入比例创历史新高，上升至85.4%，其中创新药产品销售收入同比增长约21.6%，创新药成为报告期内驱动业绩增长的主要因素。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989636","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729721","title":"港股异动 | 翰森制药涨超12%，上半年纯利同比增长35.82%，创新药收入占比超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729721","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729721?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:43","pubTimestamp":1787794987,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，$翰森制药(03692)$(03692)涨超12%。消息面上，翰森制药发布2026年中期业绩，今年上半年，公司实现收入人民币83.04亿元(单位下同)，同比增加11.71%；母公司拥有人应占溢利42.58亿元，同比增加35.82%；每股盈利0.7元，拟派发中期股息每股28.5港仙，同比增长23.1%。上半年，创新药收入约人民币70.92亿元，占收入比例约 85.4%，已成为驱动该公司业绩可持续增长的核心动力。截至2026年6月30日止六个月内，集团正在进行的创新药临床试验超过七十项，分属超过四十个候选创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486705.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药上半年纯利同比增长35.82%，创新药收入占比超85%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","MEDX","BK1161","BK1589","LNGR","BK1583","KCAI","IBBQ","06978","BK1191","159992","BK1574","BK4585","VXUS","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662297237","title":"港股异动 | 翰森制药(03692.HK)涨超10% 上半年纯利同比增长35.82% 创新药收入占比超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662297237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662297237?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:33","pubTimestamp":1787794433,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1191","06978","BK1574","03692","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184939535","title":"异动解读｜翰森制药盘中上涨5.73%，中期净利润同比大增35.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184939535","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184939535?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:30","pubTimestamp":1787794241,"startTime":"0","endTime":"0","summary":"8月27日，翰森制药盘中上涨5.73%，报33.56港元/股，成交额2706.54万港元。消息面上，公司于8月26日盘后发布中期业绩，上半年实现营收83.04亿元人民币，同比增长11.7%；股东应占溢利42.58亿元，同比大增35.8%；每股盈利0.70元，较去年同期的0.53元显著提升。业绩增长主要受创新药收入增加驱动，创新药收入占比已达85.4%，肿瘤领域贡献收入54.73亿元，占比约65.9%。此外，公司研发投入17.39亿元，同比增长20.7%，目前在研创新药临床试验超过70项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药盘中上涨，中期净利大增35.8%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662291397","title":"港股开盘向好 恒指高开0.48% 翰森制药（03692）涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662291397","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662291397?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:27","pubTimestamp":1787794022,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.48%，国企指数高开0.47%，恒生科技指数高开0.85%。翰森制药高开5.29%，公司公布截至2026年6月30日止六个月的中期业绩，股东应占溢利42.58亿元人民币，同比增长35.82%；每股基本盈利0.70人民币元。公司宣布中期分红每股普通股股息为20.5港仙。董事会已宣派以现金派付中期股息每股股份0.067港元。期内，营收22.13亿元人民币，同比增长22.06%。内地股市昨日上升，沪综指低开高走，收市上升0.6%，沪深两市成交额进一步缩减。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/ZTMxNjQ3ZDUxMTYwMDE1MDQzMDE2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/ZTMxNjQ3ZDUxMTYwMDE1MDQzMDE2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989628","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00020","03423","09067","LU2045819591.USD","03067","BK1615","07552","LU0082770016.USD","BK1109","03419","HSTECH","82800","07300","BK1612","03115","HSI","03033","03692","BK1191","LU0082770016.SGD","BK1609","LU0620787316.HKD","03032","07200","MCHmain","02833","03088","80020","83115","03417","LU0164939612.USD","03037","07226","BK1589","02837","BK1583","BK1613","09088","513600","BK1095","LU2125910500.SGD","01357","09115","02800","HHImain","07500","BK1618","LU2125910849.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662388794","title":"翰森制药：创新药龙头企业上半年收入稳健增至83.04亿元，创新药收入占比达85.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662388794","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662388794?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:32","pubTimestamp":1787736758,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1191","BK1583","BK1574","06978","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794806","title":"翰森制药(03692)发布中期业绩 股东应占溢利42.58亿元 同比增加35.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794806","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662794806?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:31","pubTimestamp":1787736670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布截至2026年6月30日止6个月的中期业绩，该集团取得收入人民币83.04亿元(单位下同)，同比增加11.71%;母公司拥有人应占溢利42.58亿元，同比增加35.82%;每股盈利0.7元，拟派发中期股息每股28.5港仙。公告称，报告期内的溢利及每股基本盈利增加，主要是由于创新药收入增加，及其他收入增加共同影响所致。截至2026年6月30日止六个月内，集团正在进行的创新药临床试验超过七十项，分属超过四十个候选创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03692","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189116419","title":"翰森制药2026年中期财报：营收83.04亿元，净利润42.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189116419","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189116419?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:26","pubTimestamp":1787736382,"startTime":"0","endTime":"0","summary":"2026年上半年，翰森制药实现营收83.04亿元，同比增长11.7%。同期净利润42.58亿元，同比增幅35.8%。其中，研发投入17.39亿元，同比增长20.7%，占总营收比重约20.9%。销售及分销开支为18.61亿元，同比提升2.3%。行政开支3.26亿元，同比下降4.8%。报告期内毛利约76.33亿元，经营活动带来约23.37亿元现金流入。肿瘤领域实现收入54.73亿元，占总营收比重约65.9%；非肿瘤领域收入28.31亿元，占比34.1%。公司将创新药增长视为驱动整体业绩上扬的主要动力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药2026年中期财报：营收83.04亿元，净利润42.58亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103414842","title":"翰森制药宣布派发中期股息，每股28.50港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=1103414842","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103414842?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:24","pubTimestamp":1787736250,"startTime":"0","endTime":"0","summary":"翰森制药集团正式宣告，将就截至六个月期间派发中期股息。每股派息金额为28.50港仙。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122174142","title":"异动解读｜翰森制药盘中下跌3.26%，报31.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122174142","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122174142?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:50","pubTimestamp":1787536227,"startTime":"0","endTime":"0","summary":"8月24日，翰森制药盘中下跌3.26%，报31.92港元/股，成交额6710.33万港元。翰森制药所在的制药行业中，个股整体表现分化。其中，石药集团涨2.23%，恒瑞医药跌1.41%，中国生物制药涨0.09%，丽珠医药跌16.45%，凯莱英跌3.17%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183213738","title":"异动解读｜翰森制药盘中下跌3.09%，报32.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183213738","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183213738?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:49","pubTimestamp":1787276960,"startTime":"0","endTime":"0","summary":"8月21日，翰森制药盘中下跌3.09%，报32.58港元/股，成交额4637.99万港元。翰森制药所在的制药行业中，个股整体表现偏弱。其中，石药集团跌3.62%，恒瑞医药跌3.06%，凯莱英跌7.64%，中国生物制药涨1.21%，绿叶制药涨0.93%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0348735423.USD","LU0067412154.USD","BK1521","LU0348783233.USD","01093","06872","IE0008368742.USD","LU1152091168.USD","LU1226287529.USD","LU1951186391.HKD","LU2097828631.EUR","LU2778985437.USD","IE00BPRC5H50.USD","IE00B031HY20.USD","01801","BK1583","IE00BZ08YS42.EUR","LU0561508036.HKD","LU0880133367.SGD","LU1328277881.USD","LU1226287792.SGD","01177","LU0463099449.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0634319403.HKD","LU2039709279.SGD","LU2097828714.EUR","09926","IE0008369823.USD","SG9999004220.SGD","LU0501845795.SGD","LU1720050803.USD","06990","LU2488822045.USD","09939","LU2097828805.USD","LU0244354667.USD","KURE","LU1226287875.USD","LU2097828474.EUR","03692","LU2242644610.SGD","02396","LU0348767384.USD","LU0540923850.HKD","LU0140636845.USD","LU2328871848.SGD","LU2097828557.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.088},{"period":"1month","weight":0.0677},{"period":"3month","weight":0.1412},{"period":"6month","weight":0.064},{"period":"1year","weight":-0.0463},{"period":"ytd","weight":-0.0416}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0118},{"period":"6month","weight":0.0003},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.0117}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002557},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012842},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033966},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005203},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039397},{"month":7,"riseRate":0.625,"avgChangeRate":0.011389},{"month":8,"riseRate":0.75,"avgChangeRate":0.028865},{"month":9,"riseRate":0.5,"avgChangeRate":-0.032361},{"month":10,"riseRate":0.142857,"avgChangeRate":0.0016},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063448},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016866}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}